THEODORA SQUIRE: Open Payments
NPI 1417591660 · GLEN ALLEN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,904 in 180 payments from 18 companies in 2025. Trend: 2023 $2,128 · 2024 $2,781 · 2025 $3,904
Food & beverage: $3,904
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 59 | $897 |
| Janssen Biotech, Inc. | 23 | $636 |
| Madrigal Pharmaceuticals | 14 | $428 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $338 |
| PFIZER INC. | 13 | $297 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $251 |
| Ardelyx, Inc. | 7 | $228 |
| GENZYME CORPORATION | 7 | $176 |
| Gilead Sciences, Inc. | 8 | $143 |
| Ethicon US, LLC | 1 | $107 |
Products named: TREMFYA, RINVOQ, REZDIFFRA, ENTYVIO, XIFAXAN, IBSRELA, DUPIXENT, VELSIPITY.
Industry payments across VA — which companies pay providers there.
